Humira (adalimumab) is a recombinant human IgG1 monoclonal antibody targeting TNF. It is used across multiple immune-mediated inflammatory diseases including rheumatoid arthritis, Crohn's disease, ulcerative colitis, psoriasis, and uveitis. The FDA first approved Humira on December 31, 2002.
Trump secured agreements with 16 pharmaceutical companies tied to TrumpRx.gov, including most-favoured-nation pricing and direct-to-patient discounts. Several companies disclosed price cuts for obesity, diabetes, insulin and other medicines.
AbbVie raised 2026 revenue and EPS guidance after first-quarter results beat estimates, with Skyrizi and Rinvoq driving growth. Humira erosion continued as neuroscience, oncology and pipeline assets supported the outlook.
AbbVie filed an sBLA for SKYRIZI as a subcutaneous induction therapy for Crohn's disease, supported by Phase 3 AFFIRM data. SKYRIZI and Rinvoq combined for $25.9B in 2025 revenue, exceeding 2027 guidance. The FDA also approved Venclexta plus acalabrutinib in CLL.
Alvotech said it will release first-quarter 2026 financial results on May 6, 2026, and host a webcast with live Q&A on May 7. The company said five biosimilars are already approved and marketed, with nine disclosed candidates in development.
Eli Lilly, AbbVie, Vertex, Gilead Sciences and Pfizer were identified as pharmaceutical stocks to watch, with Abbott Laboratories and McKesson appearing on a separate seven-stock list.
AbbVie said Skyrizi and Rinvoq generated $26.0 billion in 2025 sales and are expected to exceed $31 billion in 2026. The company said the two immunology drugs continue to offset Humira erosion and drive top-line growth.
AbbVie reported full-year adjusted EPS of $10 and total net revenue of $61.2 billion for 2025. Merit Financial Group raised its fourth-quarter stake in the company to 93,295 shares worth $21.317 million.
China’s cross-border biotech outlicensing hit US$60 billion in the first quarter of 2026. AbbVie’s up to $745 million Haisco pain deal highlights multinationals’ rising interest in Chinese drug assets.
The FDA has eased biosimilar approval procedures as these therapies have generated $56 billion in savings since 2015. New guidance eliminates comparative efficacy studies, potentially saving manufacturers $100 million per product and cutting development time by 50%. Despite growth to 23% of the biologics market, a "biosimilar void" threatens $232 billion in missed savings over the next decade.
AbbVie reported positive Phase 3 data for Skyrizi's subcutaneous Crohn's disease treatment and is advancing lutikizumab and Rinvoq in hidradenitis suppurativa, with multiple readouts expected throughout 2026 as the company pursues combination therapy strategies.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07128472 |
Evaluation of IL 12B Genetic Polymorphism (rs3213094) |
RECRUITING | NA |
| NCT06729463 |
IKBKB Gene Polymorphism (Single Nucleotide Polymorphism) (SNP) in Psoriatic and Psoriatic Arthritis Patients |
COMPLETED | NA |
| NCT06005532 |
Study Evaluation of the Efficacy, Safety and Immunogenicity of Adalimumab in Comparison With Humira® |
RECRUITING | PHASE3 |
| NCT05683626 |
Safety and Efficacy of Adalimumab Therapy for Treatment of Behcet's Disease-related Uveitis in Sohag University Hospital |
UNKNOWN | |
| NCT04135508 |
A Phase III Study Evaluate the Efficacy and Safety of BAT1406 and Humira |
COMPLETED | PHASE3 |
| NCT03651518 |
Personalized Therapies in Inflammatory Complex Disease |
COMPLETED | PHASE2 |
| NCT02871635 |
BI 695501 Versus Humira in Patients With Active Crohn's Disease: a Trial Comparing Efficacy, Endoscopic Improvement, Safety, and Immunogenicity |
COMPLETED | PHASE3 |
| NCT02850965 |
Efficacy, Safety and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis |
COMPLETED | PHASE3 |
| NCT02581345 |
Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis |
COMPLETED | PHASE3 |
| NCT02451748 |
IL-7 and IL-7R Expression in RA Patients With Active vs. Inactive Disease Treated With DMARD or CIMZIA |
COMPLETED | PHASE4 |
